Drug intelligence / Profile preview

RBI-1000

Development stage: Preclinical
Lead developer: Replicate Bioscience
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

**RBI-1000** is a preclinical self-replicating RNA (srRNA) immunotherapy developed by Replicate Bioscience for estrogen receptor-positive (ER+) breast cancer. It targets acquired resistance mutations and amplifications in ESR1, PIK3CA/PI3K, ERBB2/HER2, and ERBB3/HER3 that emerge following standard-of-care endocrine therapies. The srRNA platform elicits robust CD4+ and CD8+ T cell responses, leading to significant tumor growth inhibition and improved survival in mouse models at doses 100-fold lower than linear mRNA approaches, with plans for clinical advancement in 2024.[3][4][6]

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)ESR1 (ERα)ERBB2 (Erb-b2 receptor tyrosine kinase 2)PIK3CA (Phosphoinositide 3-kinase alpha)

Beyond the preview

Go deeper on RBI-1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBI-1000.

Explore the full profile